sapolsky_ftdupdate_mar2011

advertisement
PASS & NACC FTD Study
Daisy Sapolsky, MS, CCC-SLP
Speech Language Pathologist
MGH Frontotemporal Disorders Unit
MGH Department of Speech, Language and Swallowing Disorders & Reading Disabilities
National Alzheimer’s Coordinating Center (NACC)

NACC overview:

Alzheimer’s Disease Centers (ADCs) were
established in 1984


NACC was then established in 1999 by the
National Institute on Aging


MGH was one of the first five to receive grants
To facilitate collaborative research among the 29 ADCs
nationwide
NACC maintains a large database of the data
collected at these visits, which is a valuable
resource for ongoing research
http://www.alz.washington.edu/
National Alzheimer’s Coordinating Center (NACC)

NACC overview:

Participation in NACC involves annual visits




neurological examination and interview
neuropsychological testing
interview with a relative/friend
MGH NACC cohort includes:




709 people being actively followed
320 people with normal cognition
330 people with some form of MCI
266 people with some form of dementia
NACC FTD Study

NACC FTD study:

In pilot phase for the past year (6 centers)


MGH ready to begin administration of the NACC
FTD module
Goals:
To capture the cognitive changes of FTD through
use of a tailored evaluation
 To collect uniform data on patients with FTD
from centers across the country


data may be helpful in clinical trial design
Clinical Dementia Rating (CDR)

Tools for quantifying severity and progression
of dementia:


Clinical Dementia Rating (CDR)
5-point scale to rate stages of dementia


no cognitive impairment to severe impairment
six domains of functioning are assessed through interview
and patient performance on testing


Memory, Orientation, Judgment and Problem solving,
Community Affairs, Home and Hobbies, Personal Care
two supplemental domains added in 2006:

behavior and language
Progressive Aphasia Severity Scale (PASS)

PASS (2008)
 A “big picture” clinical tool to rate symptom
severity in a variety of speech/language
domains in people with progressive aphasia


Modeled after the CDR supplemental language
box, a rating of overall language impairment
Clinicians use their judgment to rate presence and
severity of impairment in each domain, capturing
change from the patient’s baseline
Progressive Aphasia Severity Scale (PASS)

Captures information about symptoms,
whereas performance-based testing captures
signs of impairment;
 Presumably the two together will provide
more information than either alone
Some patients perform surprisingly better on
testing than in daily life;
 Others are much more capable of
communicating in conversation than they are of
performing on tests

Progressive Aphasia Severity Scale (PASS)

All domains rated from normal to severe impairment,
like the CDR:

0 (normal), 0.5 (questionable), 1 (mild), 2 (moderate), 3 (severe)
 Articulation
 Syntax/grammar
 Fluency
 Word retrieval and expression
 Repetition
 Auditory comprehension
 Single word comprehension
 Reading
 Writing
 Functional communication
Progressive Aphasia Severity Scale (PASS)
Progressive Aphasia Severity Scale (PASS) 5.1 (Sept 16, 2009)
Patient Name:
Primary mode of expression (speech, writing, gesture, etc.):
Visit Date and Type:
Rater name:
0
normal
0.5
1
questionable/very mild impairment
mild impairment
Occasional misarticulation and/or
effortful or hesitant speech, or
dysarthria; difficulty repeating "pa ta Mild and consistent difficulty with
ka" and/or pronouncinng multi-syllabic articulation; most utterances are
words; 100% intelligible.
intelligible.
ARTICULATION: ability to say sounds and
syllables accurately and effortlessly
Normal articulation.
FLUENCY: degree to which speech flows
easily or is interupted by hesitations, fillers,
Speech is in short phrases, interrupted
pauses; reduced fluency is associated with
Speech contains occasional blank
with pauses or groping for words but
decreased phrase length and words per minute
pauses or use of fillers (umm); reduced there are occasional runs of fluent
(WPM)
Normal flow of speech. WPM and/or phrase length.
speech.
Occasional agrammatism or
SYNTAX AND GRAMMAR: use of word
paragrammatism (i.e., odd sentence
forms (run, ran), functor words (the, an), and
structure such as, "I my car drive in
Frequent agrammatism; sentence
word order when forming phrases and
your house."); may complain it is
structures are simple; frequent
sentences in most used modality (speech or
No difficulty in the use effortful to combine words into phrases misuse/ommission of grammatical
writing)
of grammar and syntax. or sentences
words or morphology
Noticeable word-finding pauses during
conversation or testing; may substitute Word finding difficulty (pauses or
a more common word or provide a
struggling) occurs several times in a 5description of the word
minute conversation; difficulty naming
WORD RETRIEVAL AND EXPRESSION: Difficulty limited to rare (circumlocution); expresses message common objects; occasional semantic
ability to express the intended word through word-finding problem or with most details; may use stereotyped or phonemic paraphasias; expresses
most used modality (speech or writing)
tip-of-the tongue feeling. phrases.
overall message with few details.
http://www.ftd-boston.org/
PASS profile: Patient A
PASS rating
3
2
Baseline
Follow up
1


Fu
nc
t
G
lo
ba
l
Ar
ti
c
Fl
ue
nc
y
S
yn
W
or
ta
d
x
R
et
ri e
va
R
l
ep
et
i ti
on
Au
Si
d
ng
C
le
om
W
p
or
d
C
om
p
R
ea
di
ng
W
ri t
in
g
0
Decline was most significant in the areas that were initially
affected while preserved domains remained areas of
strength.
Relatively fast progression of symptoms.
PASS profile: Patient B
PASS rating
3
2
Baseline
Follow up
1


Fu
nc
t
G
lo
ba
l
Ar
ti
c
Fl
ue
nc
y
S
yn
W
or
ta
d
x
R
et
ri e
va
R
l
ep
et
i ti
on
Au
Si
d
ng
C
le
om
W
p
or
d
C
om
p
R
ea
di
ng
W
ri t
in
g
0
Ratings were stable or changed only slightly (0.5) over 2
years, indicating a relatively slow rate of progression with
many areas of relative strength.
Relatively slow progression of symptoms.
Progressive Aphasia Severity Scale (PASS)

Potentially useful for:
Generating a profile of strengths and
weaknesses
 Determining PPA subtype
 Monitoring disease progression
 Capturing response to treatment in clinical
trials

speech-language therapy
 drug treatments

PASS Paper
Neurology, 2010
NDM Paper
Neurodegenerative Disease Management, 2011
PASS – Next Steps

Next steps:
Continue longitudinal analysis on the
performance of the PASS and imaging
methods as clinical and imaging markers for
diagnosis and monitoring
 Partner with other centers in the U.S. and
worldwide to use the PASS


Training materials in development
Global partners in using PASS
Northwestern University
Central Michigan University
University of
California,
San Francisco

International interest:


Nantes University Hospital, Nantes, France
War Memorial Hospital, Sydney, Australia
Questions

Questions?
Download